SCVSA Department, University of Parma, 43121 Parma, Italy.
IRCCS Ospedale San Raffaele, 20158 Milan, Italy.
Vaccine. 2021 Jul 13;39(31):4256-4260. doi: 10.1016/j.vaccine.2021.06.020. Epub 2021 Jun 12.
The first COVID-19 vaccines are being distributed to the general population. However, the shortage of doses is slowing down the goal of reaching herd immunity. The aim of the study was to verify whether previously SARS-CoV-2 infected subjects, a considerable portion of the population, should receive the same vaccination treatment of seronegative individuals.
Health-professionals either recovered from COVID-19 or never infected by SARS-CoV-2 were serologically tested at different time-points right before, and several days after, vaccination.
Previously infected individuals showed humoral immune responses, 21 days after the first dose, that was approximately 10-folds higher than the seronegative group 21 days after the second dose. Seropositivity persists for at least 11 months.
During a shortage of COVID-19 vaccine doses, previously SARS-CoV-2 infected individuals should be dispensed from the vaccination campaign. When dose availability returns to normality, injection of a single dose for seropositive individuals should be considered.
首批 COVID-19 疫苗正在向普通民众分发。然而，剂量短缺正在减缓实现群体免疫的目标。本研究的目的是验证先前感染过 SARS-CoV-2 的人群（相当一部分人口）是否应该接受与血清阴性个体相同的疫苗接种治疗。
在接种疫苗前和接种后几天，健康专业人员分别对已从 COVID-19 中康复或从未感染过 SARS-CoV-2 的人群进行血清学检测。
先前感染的个体在第一剂疫苗接种后 21 天显示出体液免疫反应，大约是血清阴性组在第二剂疫苗接种后 21 天的 10 倍。血清阳性持续至少 11 个月。
在 COVID-19 疫苗剂量短缺期间，应免除先前 SARS-CoV-2 感染的个体接种疫苗。当剂量供应恢复正常时，应考虑对血清阳性个体注射单剂疫苗。
